Treco Douglas A 4
4 · Inozyme Pharma, Inc. · Filed Mar 17, 2025
Insider Transaction Report
Form 4
Treco Douglas A
DirectorCEO & Chairman
Transactions
- Award
Stock Option (right to buy)
2025-03-11+400,000→ 400,000 totalExercise: $1.06Exp: 2035-03-10→ Common Stock (400,000 underlying) - Award
Restricted Stock Units
2025-03-11+100,000→ 100,000 total→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]The exercise price represents the closing price of the Issuer's common stock on March 11, 2025.
- [F2]The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.
- [F3]The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.